Nuvation Bio Inc. (NUVB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Nuvation Bio Inc. (NUVB) closed at USD 4.68 on 2026-10-14, a change of -12.8 % over the past year, with a market capitalization of USD 1.67B.

Nuvation Bio Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Nuvation Bio Inc. key figures

Previous close

USD 4.68 (2026-10-14)

1-year change

-12.8 %

Market cap

USD 1.67B

Enterprise value

USD 1.42B

P/E ratio (trailing)

-10.80

P/E ratio (forward)

-316.67

EPS (trailing)

-0.44

EPS (forward)

-0.02

PEG ratio

n/a

Price to book

6.54

Revenue growth

555.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

12.54

Employees

305

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Nuvation Bio Inc. and compare it with other stocks.